This study explored whether there were differences between the autoimmune disease prevalence rates in unilateral and bilateral moyamoya disease (MMD).
The authors performed a retrospective review of data obtained from the medical records of their hospital, analyzing and comparing the clinical characteristics and prevalence rates of all autoimmune diseases that were associated with unilateral and bilateral MMD in their hospital from January 1995 to October 2014.
Three hundred sixteen patients with bilateral MMD and 68 with unilateral MMD were identified. The results indicated that patients with unilateral MMD were more likely to be female than were patients with bilateral MMD (67.6% vs 51.3%, p = 0.014, odds ratio [OR] 1.99). Overall, non-autoimmune comorbidities tended to be more prevalent in the unilateral MMD cases than in the bilateral MMD cases (17.6% vs 9.8%, p = 0.063, OR 1.97, chi-square test). Autoimmune thyroid disease and other autoimmune diseases also tended to be more prevalent in the unilateral MMD cases than in the bilateral MMD cases (19.1% vs 10.8%, p = 0.056, OR 1.96 and 8.8% vs 3.5%, p = 0.092, OR 2.77, respectively, chi-square test). The overall autoimmune disease prevalence in the unilateral MMD cases was significantly higher than in the bilateral MMD cases (26.5% vs 13.6%, p = 0.008, OR 2.29, 95% CI 1.22–4.28, chi-square test). Multiple logistic regression analysis showed that autoimmune disease was more likely to be associated with unilateral than with bilateral MMD (p = 0.039, OR 10.91, 95% CI 1.13–105.25).
This study indicated a higher overall autoimmune disease prevalence in unilateral than in bilateral MMD. Unilateral MMD may be more associated with autoimmune disease than bilateral MMD. Different pathogenetic mechanisms may underlie moyamoya vessel formation in unilateral and bilateral MMD.
INCLUDE WHEN CITING Published online September 25, 2015; DOI: 10.3171/2015.4.JNS142936.
Disclosure The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper.
Ahn IM, , Park DH, , Hann HJ, , Kim KH, , Kim HJ, & Ahn HS: Incidence, prevalence, and survival of moyamoya disease in Korea: a nationwide, population-based study. Stroke 45:1090–1095, 2014
Bower RS, , Mallory GW, , Nwojo M, , Kudva YC, , Flemming KD, & Meyer FB: Moyamoya disease in a primarily white, Midwestern US population: increased prevalence of autoimmune disease. Stroke 44:1997–1999, 2013
Duan L, , Bao XY, , Yang WZ, , Shi WC, , Li DS, & Zhang ZS, et al.: Moyamoya disease in China: its clinical features and outcomes. Stroke 43:56–60, 2012
Fukui M: Guidelines for the diagnosis and treatment of spontaneous occlusion of the circle of Willis (‘moyamoya’ disease) Research Committee on Spontaneous Occlusion of the Circle of Willis (Moyamoya Disease) of the Ministry of Health and Welfare, Japan. Clin Neurol Neurosurg 99:Suppl 2 S238–S240, 1997
Hayashi K, , Horie N, , Izumo T, & Nagata I: A nationwide survey on unilateral moyamoya disease in Japan. Clin Neurol Neurosurg 124:1–5, 2014
Hayashi K, , Horie N, , Suyama K, & Nagata I: An epidemiological survey of moyamoya disease, unilateral moyamoya disease and quasi-moyamoya disease in Japan. Clin Neurol Neurosurg 115:930–933, 2013
Houkin K, , Abe H, , Yoshimoto T, & Takahashi A: Is “unilateral” moyamoya disease different from moyamoya disease?. J Neurosurg 85:772–776, 1996
Jiang T, , Perry A, , Dacey RG Jr, , Zipfel GJ, & Derdeyn CP: Intracranial atherosclerotic disease associated with moyamoya collateral formation: histopathological findings. J Neurosurg 118:1030–1034, 2013
Kainth DS, , Chaudhry SA, , Kainth HS, , Suri FK, & Qureshi AI: Prevalence and characteristics of concurrent down syndrome in patients with moyamoya disease. Neurosurgery 72:210–215, 2013
Kazumata K, , Ito M, , Tokairin K, , Ito Y, , Houkin K, & Nakayama N, et al.: The frequency of postoperative stroke in moyamoya disease following combined revascularization: a single-university series and systematic review. J Neurosurg 121:432–440, 2014
Kelly ME, , Bell-Stephens TE, , Marks MP, , Do HM, & Steinberg GK: Progression of unilateral moyamoya disease: A clinical series. Cerebrovasc Dis 22:109–115, 2006
Kim JM, , Jung KH, , Sohn CH, , Park J, , Moon J, & Han MH, et al.: High-resolution MR technique can distinguish moyamoya disease from atherosclerotic occlusion. Neurology 80:775–776, 2013
Kim SJ, , Heo KG, , Shin HY, , Bang OY, , Kim GM, & Chung CS, et al.: Association of thyroid autoantibodies with moyamoya-type cerebrovascular disease: a prospective study. Stroke 41:173–176, 2010
Kuroda S, & Houkin K: Moyamoya disease: current concepts and future perspectives. Lancet Neurol 7:1056–1066, 2008
Leno C, , Mateo I, , Cid C, , Berciano J, & Sedano C: Autoimmunity in Down’s syndrome: another possible mechanism of moyamoya disease. Stroke 29:868–869, 1998
Li H, , Zhang ZS, , Dong ZN, , Ma MJ, , Yang WZ, & Han C, et al.: Increased thyroid function and elevated thyroid autoantibodies in pediatric patients with moyamoya disease: a case-control study. Stroke 42:1138–1139, 2011
Sasaki T, , Nogawa S, & Amano T: Co-morbidity of moyamoya disease with Graves’ disease Report of three cases and a review of the literature. Intern Med 45:649–653, 2006
Scott RM, & Smith ER: Moyamoya disease and moyamoya syndrome. N Engl J Med 360:1226–1237, 2009
Suzuki S, , Mitsuyama T, , Horiba A, , Fukushima S, , Hashimoto N, & Kawamata T: Moyamoya disease complicated by Graves’ disease and type 2 diabetes mellitus: report of two cases. Clin Neurol Neurosurg 113:325–329, 2011
Tendler BE, , Shoukri K, , Malchoff C, , MacGillivray D, , Duck-row R, & Talmadge T, et al.: Concurrence of Graves’ disease and dysplastic cerebral blood vessels of the moyamoya variety. Thyroid 7:625–629, 1997
Uchino K, , Johnston SC, , Becker KJ, & Tirschwell DL: Moyamoya disease in Washington State and California. Neurology 65:956–958, 2005
Utku U, , Asil T, , Celik Y, & Tucer D: Reversible MR angiographic findings in a patient with autoimmune Graves disease. AJNR Am J Neuroradiol 25:1541–1543, 2004
Wang R, , Xu Y, , Lv R, & Chen J: Systemic lupus erythematosus associated with moyamoya syndrome: a case report and literature review. Lupus 22:629–633, 2013
Watanabe C, , Oishi T, , Yamamoto T, , Sasaki K, , Tosaka M, & Sato T, et al.: Chorea and Broca aphasia induced by diabetic ketoacidosis in a type 1 diabetic patient diagnosed as moyamoya disease. Diabetes Res Clin Pract 67:180–185, 2005
| All Time | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 289 | 289 | 61 |
| Full Text Views | 1929 | 167 | 1 |
| PDF Downloads | 1170 | 126 | 1 |
| EPUB Downloads | 0 | 0 | 0 |